Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

Exclusion Criteria

• •Female patients who are either pregnant or breastfeeding.
• •Women of childbearing potential who are not using a specified birth control method
• •Patients discontinued prematurely from the MS-F204 study
• •Patients with a history of seizures or with evidence of past, or possible epileptiform activity on an EEG
• •Patient with either a clinically significant abnormal ECG or laboratory values at the MS-F204 EXT screening visit
• •Patient with severe renal impairment
• •Patient with angina, uncontrolled hypertension, clinically significant cardiac arrhythmias, or any other clinically significant cardiovascular abnormality, as judged by the Investigator
• •Patient with a known allergy to pyridine-containing substances or any of the inactive ingredients of the Fampridine-SR tablet
• •Patient who has received an investigational drug (other than Fampridine-SR or placebo under MS-F204 study) within 30 days of the MS-F204EXT screening visit or a patient who is scheduled to enroll in an investigational drug trial at any time during this study
• •Patient who has a history of drug or alcohol abuse within the past year